logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
P

Pharmacoeconomics-Open

IF2.1
Papers53
Citations
Journal Papers 53
Publication Date
delete
Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deletePalmer, Andrew J.; Zhao, Ting; Henson, Glen; Ahmad, Hasnat; Taylor, Bruce V.; van der Mei, Ingrid; Campbell, Julie A.
deleteShare
deleteSave
Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteKebede, Bezie; Bahiru, Bereket; Tafere, Chernet
deleteShare
deleteSave
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete1
deleteOAAI
deleteFlanigan, Jeanine; Kane, Sarah; Fashami, Fatemeh Mirzayeh; Zhou, Anna; Almuallem, Lamees; Tindal, Mike; Schauf, Marion; Li, Edward; Lyman, Gary H.
deleteShare
deleteSave
Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteBezdenezhnykh, Tatiana; O'Mahony, James F.; Jacob, Benjamin M.; Redmond, Patrick
deleteShare
deleteSave
Trial-Based Economic Evaluations Conducted alongside Studies Embedded in Australian Healthcare Services and Programs: A Scoping Review
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteWang, Belinda; Sherrington, Catherine; Pivotto, Luiza R.; Saputra, Stanley; Comachio, Josielli; Scarfe, Joanne; Szewczyk, Zoe; Costa, Nathalia; Pearce, Alison; Hassett, Leanne; Milat, Andrew; Williams, Christopher; Kwok, Wing S.; Yu, Justin; Howard, Kirsten; Pinheiro, Marina B.
deleteShare
deleteSave
Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteLim, Zhi Zhen; Lim, Yan Ling; Wang, Furene Sijia; Ling, Simon Robert; Tay, Stacey Kiat Hong; Wang, Yi
deleteShare
deleteSave
Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop
deletePharmacoeconomics-Open
IF2.1
delete2026-07-01
delete0
deleteOAAI
deleteMcQueen, R. Brett; Cohen, Benjamin; Kacergis, Caroline; Kennedy, Eileen; Rosettie, Katherine L.
deleteShare
deleteSave
A Micro-costing Study of Community-Based Primary HPV Self-Sampling and Triage Test for Cervical Cancer Screening in Rural Cambodia
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteZhang, Ziyue; Bussmann, Hermann; Vong, Sathiarany; Kol, Hero; von Knebel Doeberitz, Magnus; De Allegri, Manuela; Singh, Kavita
deleteShare
deleteSave
Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteChen, Jinyu; Zhang, Yichen; Han, Kexin; Han, Sheng; Shi, Luwen; Guan, Xiaodong
deleteShare
deleteSave
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? (mar, 10.1007/s41669-026-00642-1, 2026)
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteRodriguez-Lago, Iago; Peinado-Fabregat, Jose Ignacio; Guigini, Marcelo; Cerezales, Monica; Ibanez, Francisco; Crespo, Carlos; Barreiro-de Acosta, Manuel
deleteShare
deleteSave
Exploring the Sensitivity of Utilities Predicted by theEQ-5D, SF-6D, HUI3, 15D, AQoL-4D, and AQoL-8D Multi-Attribute UtilityInstruments to SF-36 Dimensions
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
deleteOAAI
deleteTetteh, Josephine N. A.; Schlander, Michael
deleteShare
deleteSave
Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of Obesity
deletePharmacoeconomics-Open
IF2.1
delete2026-05-01
delete0
PREAI
deleteModley, Ben; Seddik, Ahmed; Evans, Marc; Stephens, Stephanie; Salter, Chloe; Appierto, Marilena
deleteShare
deleteSave
Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis
deletePharmacoeconomics-Open
IF2.1
delete2026-04-01
delete0
PREAI
deleteHuang, Min; Romdhani, Hela; Song, Yan; Xie, Jipan; Sundaresan, Sanjana; Liu, Daisy; Rowen, Donna; Elbasha, Elamin H.; Mohanty, Salini; Kelly, Matthew S.
deleteShare
deleteSave
Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteHamamah, Samir; Carette, Jeremy; Leleu, Henri; Markert, Marie
deleteShare
deleteSave
Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteZarkadoulas, Eleftherios; Silva, Fabio; Alves, Joana; Madeira, Francisco; Postma, Maarten J.
deleteShare
deleteSave
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis (jan, 10.1007/s41669-025-00612-z, 2026)
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteScavina, Mena; Posner, Nate; Dorling, Patricia; Talaga, Anna; Stachel, Anna; Alvir, Jose
deleteShare
deleteSave
Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteTkacz, Joseph; Cajigal, Alejandro; Sidovar, Matthew; Wilson, Kathleen; Pennington, Emma; Okunev, Ilya; Gillard, Kristin
deleteShare
deleteSave
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete1
PREAI
deleteRodriguez-Lago, Iago; Peinado-Fabregat, Jose Ignacio; Guigini, Marcelo; Cerezales, Monica; Ibanez, Francisco; Crespo, Carlos; Acosta, Barreiro-de
deleteShare
deleteSave
Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States
deletePharmacoeconomics-Open
IF2.1
delete2026-03-01
delete0
PREAI
deleteBaljoon, Ahmead; Diaby, Vakaramoko; Suther, Sandra; Dutton, Matthew; Ali, Askal; Eljilany, Islam
deleteShare
deleteSave
Valuing Maintenance of Visual Function in Retinitis Pigmentosa: A Discrete Choice Experiment with Patients and the General Public
deletePharmacoeconomics-Open
IF2.1
delete2026-02-01
delete0
deleteOAAI
deleteMarsh, Kevin; Trapali, Myrto; Ingham, Mike; Martin, Silas
deleteShare
deleteSave